{"entity":{"id":"pold2","kind":"target","name":"POLD2","aka":["DNA polymerase delta 2, accessory subunit","DNA polymerase delta subunit 2"],"tldr":"POLD2 (DNA polymerase delta subunit 2) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.","summary":"Accessory component of both the DNA polymerase delta complex and the DNA polymerase zeta complex. As a component of the trimeric and tetrameric DNA polymerase delta complexes (Pol-delta3 and Pol-delta4, respectively), plays a role in high fidelity genome replication, including in lagging strand synthesis, and repair. Pol-delta3 and Pol-delta4 are characterised by the absence or the presence of POLD4.\n\nOpen Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.73, genetic association 0.00, clinical 0.99).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9176","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9176"},{"label":"UniProt P49005","url":"https://www.uniprot.org/uniprotkb/P49005/entry"},{"label":"NCBI Gene 5425","url":"https://www.ncbi.nlm.nih.gov/gene/5425"},{"label":"Ensembl ENSG00000106628","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106628"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["leukaemia","non-hodgkin-lymphoma","lung-cancer","myeloproliferative-neoplasms","breast-cancer","ovarian","mds","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99; UniProt keyword \"DNA repair\". Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"POLD2","role":["drug-target","dna-repair"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9176","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9176","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P49005","url":"https://www.uniprot.org/uniprotkb/P49005/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000106628","url":"https://platform.opentargets.org/target/ENSG00000106628/associations","note":"association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.60, ovarian cancer 0.58, acute myeloid leukaemia 0.59, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.60 (GraphQL API, CC0)"}],"hgnc":"HGNC:9176","ensembl":"ENSG00000106628","uniprot":"P49005","entrez":"5425","biology":"Accessory component of both the DNA polymerase delta complex and the DNA polymerase zeta complex. As a component of the trimeric and tetrameric DNA polymerase delta complexes (Pol-delta3 and Pol-delta4, respectively), plays a role in high fidelity genome replication, including in lagging strand synthesis, and repair. Pol-delta3 and Pol-delta4 are characterised by the absence or the presence of POLD4. They exhibit differences in catalytic activity. Most notably, Pol-delta3 shows higher proofreading activity than Pol-delta4. Although both Pol-delta3 and Pol-delta4 process Okazaki fragments in vitro, Pol-delta3 may also be better suited to fulfill this task, exhibiting near-absence of strand displacement activity compared to Pol-delta4 and stalling on encounter with the 5'-blocking oligonucleotides. Location: Nucleus (UniProt). Locus 7p13 (HGNC).","whereFound":["Leukaemia: Open Targets association 0.61 with leukaemia (MONDO_0005059)","Non-Hodgkin lymphoma: Open Targets association 0.60 with non-Hodgkin lymphoma (MONDO_0018908)","Lung cancer: Open Targets association 0.60 with lung cancer (MONDO_0008903)","Myeloproliferative neoplasms: Open Targets association 0.59 with myeloproliferative neoplasm (MONDO_0020076)","Breast cancer: Open Targets association 0.59 with breast cancer (MONDO_0007254)","Ovarian cancer: Open Targets association 0.58 with ovarian cancer (MONDO_0008170)"],"targetClass":"other","prevalence":[]},"route":"/targets/pold2/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}]}}